Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 1
2012 3
2014 1
2015 3
2016 1
2017 2
2018 2
2019 2
2020 1
2021 1
2022 4
2023 2
2024 5
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Miller PD, et al. J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. J Bone Miner Res. 2022. PMID: 35466448 Free PMC article. Clinical Trial.
In both trials, the least-square mean percent change from baseline BMD was significantly greater in the romosozumab groups versus controls across all kidney function categories at month 12. Romosozumab reduced the relative risk of new vertebral fractures at month 12 among …
In both trials, the least-square mean percent change from baseline BMD was significantly greater in the romosozumab groups versus controls a …
The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers.
Abrahamsen B, Ernst MT, Smith CD, Nybo M, Rubin KH, Prieto-Alhambra D, Hermann AP. Abrahamsen B, et al. Bone. 2020 Aug;137:115371. doi: 10.1016/j.bone.2020.115371. Epub 2020 Apr 22. Bone. 2020. PMID: 32334104
BACKGROUND: Management of osteoporosis given reduced renal function is one of the largest challenges in the bone clinic. OBJECTIVES: Identify the cut-off for renal function below which there would be no overall BMD benefit associated with bisphospho …
BACKGROUND: Management of osteoporosis given reduced renal function is one of the largest challenges in the bone clinic. OBJEC …
Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese Osteoporosis Intervention Trial-05.
Takeuchi Y, Tanaka S, Kuroda T, Hagino H, Mori S, Soen S. Takeuchi Y, et al. Osteoporos Int. 2024 Dec;35(12):2175-2182. doi: 10.1007/s00198-024-07260-9. Epub 2024 Sep 30. Osteoporos Int. 2024. PMID: 39343826 Free PMC article. Clinical Trial.
The association of renal function with fracture incidence during teriparatide or alendronate treatment in elderly Japanese women was examined. Fracture incidence differed by fracture type, renal function, and treatment protocol. The results provide imp …
The association of renal function with fracture incidence during teriparatide or alendronate treatment in elderly Japanese wom …
The effect of bisphosphonates on kidney function in osteoporotic geriatric patients with impaired renal function.
Tweekittikul A, Srinonprasert V, Sura-Amonrattana U. Tweekittikul A, et al. BMC Geriatr. 2025 Dec 23;25(1):1041. doi: 10.1186/s12877-025-06689-9. BMC Geriatr. 2025. PMID: 41437225 Free PMC article.
OBJECTIVES: To evaluate the real-world renal safety of bisphosphonates in older adults with discrepant renal function estimates (eGFR 35 mL/min/1.73 m2 vs. ...These findings suggest that bisphosphonates may be used cautiously in selecte …
OBJECTIVES: To evaluate the real-world renal safety of bisphosphonates in older adults with discrepant renal functio …
Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis.
Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, Eastell R, Walsh JS. Schini M, et al. Osteoporos Int. 2022 Mar;33(3):737-744. doi: 10.1007/s00198-021-06160-6. Epub 2021 Oct 15. Osteoporos Int. 2022. PMID: 34654939 Free article.

Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2019 stated that CrCl and not estimated glomerular filtration rate (eGFR) should be used and that treatment should not be given if CrCl < 35 ml/min. The objective of this study was to compa

…
Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2019 stated that CrCl and not estimated glomerular filtrati …
Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.
Vescini F, Borretta G, Chiodini I, Boniardi M, Carotti M, Castellano E, Cipriani C, Eller-Vainicher C, Giannini S, Iacobone M, Salcuni AS, Saponaro F, Spiezia S, Versari A, Zavatta G, Mitrova Z, Saulle R, Vecchi S, Antonini D, Basile M, Giovanazzi A, Paoletta A, Papini E, Persichetti A, Samperi I, Scoppola A, Novizio R, Calò PG, Cetani F, Cianferotti L, Corbetta S, De Rimini ML, Falchetti A, Iannetti G, Laureti S, Lombardi CP, Madeo B, Marcocci C, Mazzaferro S, Miele V, Minisola S, Palermo A, Pepe J, Scillitani A, Tonzar L, Grimaldi F, Cozzi R, Attanasio R. Vescini F, et al. Endocr Metab Immune Disord Drug Targets. 2024;24(8):991-1006. doi: 10.2174/0118715303260423231122111705. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38644730 Free PMC article.
Osteoporosis disclosed by DXA examination and/or any fragility fracture. Renal function impairment (eGFR <60 mL/min). Clinic or silent nephrolithiasis. Age 50 years. ...
Osteoporosis disclosed by DXA examination and/or any fragility fracture. Renal function impairment (eGFR <60 mL/mi …
Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.
Wung CH, Liu HY, Tsai TT, Chen JJ. Wung CH, et al. Front Pharmacol. 2025 Jun 17;16:1569744. doi: 10.3389/fphar.2025.1569744. eCollection 2025. Front Pharmacol. 2025. PMID: 40599806 Free PMC article.
Three AODs: sclerostin inhibitors, bisphosphonates and parathyroid hormone (PTH) analogs were associated with mild but significantly increased BMD at the lumbar spine, total hip, and femoral neck. ...The five AODs had no significant effect on eGFR. CONCLUSION: We de …
Three AODs: sclerostin inhibitors, bisphosphonates and parathyroid hormone (PTH) analogs were associated with mild but significantly …
Renal Outcomes and Dosage Considerations Associated with Bisphosphonate Use: A Systematic Review of Randomized Clinical Trials.
Venkatasubramanian P, Raju R, Biatris PS, Chander SJU. Venkatasubramanian P, et al. Res Sq [Preprint]. 2026 May 18:rs.3.rs-9724722. doi: 10.21203/rs.3.rs-9724722/v1. Res Sq. 2026. PMID: 42239793 Free PMC article. Preprint.
With age-related bone disorders and renal insufficiency becoming more prevalent worldwide, understanding the effect of bisphosphonates on patients with compromised renal function becomes inevitable. ...Even though bisphosphonates are safer to us …
With age-related bone disorders and renal insufficiency becoming more prevalent worldwide, understanding the effect of bisphosphon …
Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study.
Ma Y, Xu S, Xu Z, Zhang Y, Lu C, Chen D, Wang Q. Ma Y, et al. Endocrine. 2024 Feb;83(2):459-465. doi: 10.1007/s12020-023-03567-5. Epub 2023 Nov 16. Endocrine. 2024. PMID: 37971631

Baseline and the changes in renal function within 1 year following infusions were collected, the incidence of renal impairment (eGFR < 60 mL/min/1.73 m(2) or a > 25% reduction in the eGFR from baseline) was noted and the risk factors were

…
Baseline and the changes in renal function within 1 year following infusions were collected, the incidence of renal imp …
Risk factors for osteonecrosis of the jaw in patients with chronic kidney disease: a nested case-control study.
Iseri K, Hida N. Iseri K, et al. J Bone Miner Res. 2025 Feb 2;40(2):262-269. doi: 10.1093/jbmr/zjae193. J Bone Miner Res. 2025. PMID: 39656914
CKD patients were identified based on estimated glomerular filtration rate (eGFR) measurements, and ONJ cases were identified using ICD-10 codes and diagnostic terms. ...When stratified by indications for bisphosphonate use (known to be eliminated by renal ex …
CKD patients were identified based on estimated glomerular filtration rate (eGFR) measurements, and ONJ cases were identified using I …
33 results